Biohaven is a clinical-stage company developing BHV-1300, an IgG degrader in Phase 3 for Graves' disease, and other immunology, neurology and cancer programs; none are approved.
Biohaven's original case, troriluzole for spinocerebellar ataxia, ended in a Complete Response Letter in November 2025, which Biohaven is appealing. The case now rests on its degrader platform, led by BHV-1300 in a pivotal Phase 3 in Graves' hyperthyroidism, which Ono licensed for Japan and other Asian markets in October. FDA paused new enrollment in opakalim studies with a partial clinical hold, while the fully enrolled RISE3 epilepsy trial reports in the second half of 2026.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: BHV-1300 normalizes thyroid hormones in the Phase 3
Does BHV-1300 bring thyroid hormones to normal without antithyroid drugs?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Biohaven licensed opakalim to SK Biopharmaceuticals and BHV-1300 in Asia to Ono, funding its Graves' disease Phase 3 after the troriluzole rejection
Biohaven's Graves' disease degrader carries the pipeline after troriluzole's CRL; the 2027 Phase 3 readout is the make-or-break event
Pivotal epilepsy readout is the first test of a platform rebuilt after troriluzole's CRL, with a $270M cash pile burning at $118M per quarter
Biohaven's Kv7 activator holds the pipeline together, but delayed MDD data and ~3.5 quarters of cash at current burn define the window
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Breast and gynecologic cancers, Other cancers, Kidney diseases, Neuromuscular diseases, Neurology and pain, Psychiatric disorders, Obesity, diabetes and heart disease, Autoimmune and inflammatory diseases, Endocrine and bone diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
48 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.